tDCS to Decrease Opioid Relapse (UH3)

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Opioid Use Disorder
Interventions
DEVICE

active tDCS

The anode will be placed over the right DLPFC (F4 on the EEG 10-20 system) and the cathode over the left DLPFC65 (F3) using 25cm2 sponges at an intensity of 2mA. Stimulation will be delivered for 20 minutes via two saline-soaked surface sponge electrodes and a battery-driven, constant current stimulator (NeuroConn DC Stimulator Plus).

DEVICE

sham tDCS

Same device and procedures as active tDCS with the exception that the device includes a study mode, in which subject-specific codes are entered to deliver active or sham stimulation, keeping the administrator blinded. Sham stimulation will use a method in which stimulation will be ramped up and back down over a 30-second period at the beginning and end of sham tDCS.

Trial Locations (1)

02906

RECRUITING

Butler Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Butler Hospital

OTHER